Connect with us

Press Release

China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies

Published

5 hours ago

on

China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies

 

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.

 

Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.

 

Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.

 

CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.

 

More information about Vecantoxatug and Tetanus

Vecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc).  TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.

 

Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].

 

C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, – tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)₂), and human tetanus immunoglobulin (HTIG) – face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.

 

More information about Silevimig and Rabies

Silevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.

 

In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.

 

Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].

 

Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.

 

About GENRIX BIO

Genrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

 

Reference:

  1. China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.001
  2. Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People’s Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.001
  3. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…
  4. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.004
  5. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

The Second Chu Culture Festival Opens in Jingzhou, China

Published

1 hour ago

on

September 23, 2025

By

On the evening of September 20, the opening ceremony of the Second Chu Culture Festival was held in Jingzhou, China. The event was guided by the China Public Diplomacy Association, the China Federation of Cultural Promotion, and the Cultural Communication Committee of the China Cultural Management Association, hosted by the CPC Jingzhou Municipal Committee and the Jingzhou Municipal People’s Government, and organized by Hubei Radio and Television Station.

Cultural scholars from home and abroad, diplomats from multiple countries stationed in China, international youth representatives, elite Chu entrepreneurs, figures from the literary and art circles, and Jingzhou citizens gathered together for a grand Chu culture celebration that bridged the ancient and the modern, blending China and the world.

As an important component of the long-standing Chinese civilization, Jingchu culture holds a crucial place in its historical development. The Second Chu Culture Festival, themed “Let the World See Chu Culture”, seeks to vividly showcase the Yangtze River civilization through the inheritance and innovation of Chu culture. The festival aims to propel Jingchu culture “beyond its circle and across the seas,” enabling more people to appreciate the unique charm of Chinese and Yangtze River civilizations, to understand “Why Jingchu?” and “Why China?” through the glory of history and the reflection across millennia.

The opening ceremony took Chu lacquerware, bamboo slips, and Chu embroidery as narrative threads, unfolding in three chapters: “Beautiful Jingzhou, Waiting in Lacquer”, “History on the Slips, Understanding China”, and “Splendid Rivers and Mountains, Robes of Unity.” These showcased three iconic cultural treasures from the land of Chu.

The ceremony began with the Chu-style welcoming song-and-dance performance “Arrival of the Phoenix”, recreating the grandeur of ancient Chu welcoming rituals with graceful ceremonies and elegant dances. On the large stage screen, phoenix feathers extended toward the audience, and light and shadow evoked the majestic vision of “A phoenix sings over Chu, soaring across the heavens.”

Three unique “treasures” were unveiled, integrating national-level cultural relics with modern technology to interpret the profound legacy of Chu culture.

The first treasure, the painted wooden lacquer artifact Toad-Base Phoenix Bird with Feathered Man, made a stunning debut. Aerospace film director Zhu Yiran, polar explorer He Pengfei, and aerospace new-material researcher Cao Genyang each took the stage to share insights inspired by this relic—through film clips, polar experiences, and even a “stone-carved moon flag.” In their narratives, the Chu artifact became a living cultural messenger, breathing romance and grandeur.

The second treasure, the Chu bamboo slips, was equally awe-inspiring. Renowned cultural scholar Xiong Zhaozheng, appearing as a “Guardian of Yangtze Culture,” explained that “The Chu slips are a cultural gene living in the present.” He called upon future generations to “continue writing the archive.” Then, Zhang Han, a young Jingzhou-born dancer, performed the martial arts piece “One Slip, A Thousand Years”, using a blend of strength and grace to bring Chu script to life and demonstrate the contemporary inheritance of cultural bloodlines.

The third treasure focused on the artistry of Chu embroidery. Jingzhou-born actress and Chu culture ambassador Zeng Li warmly introduced Chu silk in her local dialect: “It is light, as light as cicada wings; it is heavy, carrying over two thousand years of time.” Following this, the Warring States robe showcase “Splendid Rivers and Mountains” featured exquisitely recreated Chu garments, allowing the audience to travel back in time to experience Chu people’s aesthetic wisdom and lifestyle beauty.

The opening ceremony also carried strong international elements. A launch event titled “Latin America and the Caribbean Delegation in Jingzhou” was held, where representatives from 16 countries jointly raised a symbolic key of friendship and cooperation to unlock Jingzhou’s ancient yet modern charm. During the festival, they will experience the deep fusion of “Jingchu Spirit” and “Latin American Passion.”

Another highlight was the flag presentation ceremony for the “First International Youth Yangtze Journey.” Guests from China and abroad presented flags to outstanding young representatives from 13 countries including Argentina, Brazil, Egypt, and Hungary, who will embark on a journey from Jingzhou along the Yangtze River to better understand China.

The entire opening ceremony was a visual and auditory feast. The opening dance “Arrival of the Phoenix” showcased the beauty of Eastern etiquette through grand Chu-style rituals; “The Spirit of Lacquer” expressed the elegance of lacquerware through graceful movements; and the mass recitation “Echoes of Millennia” resounded with powerful voices that stirred hearts.

In the finale, inspired by the camel-rider lamp—an iconic artifact symbolizing Chu people’s external exchanges—Chinese and international guests together lit the “Lamp of Inheritance,” the “Lamp of Friendship,” the “Lamp of Peace,” and the “Lamp of Civilization,” symbolizing mutual learning and everlasting friendship. The closing performance “Let the World See” brought the atmosphere to its peak, conveying Jingzhou’s firm confidence in connecting the world through culture and opening the future through innovation.

During the festival, eight major themed sections with more than 20 activities will be held, covering cultural exchange, academic seminars, public performances, and business cooperation. Highlights include the “Chu Merchants Homecoming and Jingzhou 2025 Chu Business Conference & Major Project Signing,” the CCTV “Bosom Friends Hubei · Chu Charm Jingzhou” Autumn Concert, the “Most Beautiful Warring States Robe Travel Photography Season” awards, the “Yijing Jing’en Intangible Heritage Exhibition and Performance,” and the “Brilliant Yangtze” Eastern Zhou Archaeology Exhibition. These events will present Jingzhou’s deep historical heritage and modern vitality to the world.

By gathering momentum through the festival, leveraging it as a bridge, empowering development, and benefiting the people, Jingzhou is focusing on building a strong regional hub. Through the festival as a breakthrough point, the city promotes the study, interpretation, and dissemination of Chu culture, continually advancing its protection, inheritance, and global reach. Jingzhou is committed to becoming an authoritative center for interpreting Chu culture in the new era, a stage for immersive experiences, a hub of activities, and a destination for cultural tourism—enhancing its cultural influence and contributing strong momentum to “building a pioneering area and being a vanguard.”

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Zeagoo’s 12th Anniversary Grand Collaboration with Maye Musk: Early Autumn Fashion Guide First Release

Published

2 hours ago

on

September 23, 2025

By

As early autumn arrives, the global women’s apparel brand Zeagoo celebrates its 12th Anniversary. Since its founding, Zeagoo has always stood by “Be Different, Be You,’”upholding its mission to create comfortable and fashionable apparel for mature women. It aims to convey a brand philosophy of easy, comfortable self-expression and self-realization.

At this landmark moment, Zeagoo officially announces September 22nd as its 12th Anniversary celebration day. This celebration is highlighted by the launch of the “Zeagoo X Maye Musk’”2025 Early Autumn Zeagoo Fall Style Guide, a collaboration with the internationally renowned model, Doctor of Dietetics, and entrepreneur, Maye Musk. The guide helps women aged 35+ discover comfortable, stylish, and inspiring outfit ideas.

Maye Musk: A Paragon of Independent Women

At over 70, Maye Musk is a globally acclaimed supermodel, Doctor of Dietetics, and entrepreneur who has broken conventional perceptions of age. Her independent and resilient spirit aligns perfectly with Zeagoo’s philosophy. Zeagoo has always focused on the diverse needs of women aged 35+, whether they require professional looks for the workplace, comfortable wear for daily life, or unique styles for social events.

Reflecting on her own journey through those years, Maye quickly accepted the collaboration, stating, “These designs are for women 35+. When I was that age and older, I needed to look stylish on a small budget. These clothes would’ve been perfect for me. Thank you, Zeagoo, for caring for us.” This collaboration is a union of shared values, aiming to guide more women to find their own path where comfort and style.

MayeMusk Picks:  Early Autumn Staples

In the “Zeagoo X Maye Musk” 2025 Early Autumn Zeagoo Style Guide, Maye Musk has carefully selected several comfortable and stylish pieces, including outerwear, a top, and a skirt. These items cater to the diverse early autumn needs of women aged 35+, with each one showcasing Zeagoo’s exceptional craftsmanship and stylish design.

Item 1: Zeagoo Women’s Zip Up Hoodies Oversized Fleece Long Tunic Sweatshirts

This full-zip hoodie is an essential piece for any early autumn wardrobe. Not only has it been featured in Maye’s fall favorites recommendations from Zeagoo, but it has also received official recognition—it was specifically recommended as a top fashion pick for moms on the FOX29 Good Day Philadelphia segment, ‘Back-to-School Must-Haves.’

  • Comfortable Fabric:Elastic fleece material is skin-friendly and breathable, allowing for unrestricted movement.
  • Versatile Wearing: The knee-length full-zip design enables multiple styling options, such as a jacket or an overlayer, for effortless style transitions.
  • Practical Design: The oversized fit with large pockets combines personality and functionality.

Item 2: Zeagoo Womens 2025 Fall Sweaters

With its soft texture and stylish design, this Zeagoo knit sweater is a perfect addition to your Zeagoo Fall Style—ideal for both layering and solo wear in early autumn. It’s also featured in Maye’s fall favorites from Zeagoo.Premium Material: A soft, lightweight, and breathable blend of viscose, polyester, and polyamide for lasting comfort and a flattering fit.

  • Chic Design: Features a loose fit and V-neck that elongates the neck, with detailed lantern sleeves, cable-knit, and hollow-out patterns for added texture and style.
  • Versatile Styling: Perfect for both professional and casual settings. Wear it solo or layered, and pair it with various bottoms—ideal for work, meetings, or outings.

Item 3: Zeagoo Skirts for Women High Waist Skirt Elegant Midi Skirt Satin

This skirt, with its premium material and slimming design, is a key piece for elevating any early autumn outfit.

  • Material & Fit: Made of skin-friendly, breathable satin with mid-weight thickness ideal for early autumn. Available in maxi and midi lengths to suit different body types.
  • Slimming Design:High-waisted cut visually elongates the figure and enhances curves. The minimalist design exudes elegant maturity suitable for various occasions.
  • Styling Options: Easily paired with boots and sweaters in autumn/winter, or sandals and camisoles in warmer months. Perfect for daily wear, work, parties, and vacations.

Dual-Channel Celebration: Thanking Our Companions, Embracing the Future

Celebrating Zeagoo 12th Anniversary, the brand hosts the American Dreams Hot Sale and launches the new Zeagoo Fall Style Guide with Maye Musk.

From September 19–20, Zeagoo opens the American Dreams Hot Sale pop-up at the American Dream Mall atrium in New Jersey, featuring collaborations with EKOUAER, COOFANDY, Arshiner, and PINSPARK for an immersive in-person shopping experience.

Zeagoo remains committed to its core philosophy, “Be Different, Be You,” and its original mission to create comfortable and stylish apparel for mature women. From the impactful collaboration with Maye Musk to the special anniversary events, Zeagoo is dedicated to empowering women aged 35+ worldwide, enabling them to confidently express themselves in every aspect of life and convey their charm through their fashion choices.

For more information, please visit the Zeagoo website and Amazon storefront, or connect with Zeagoo on Facebook and Instagram.

Zeagoo

Charlotte Liu

pr@zeagoo.com

New York, US

https://zeagoo.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

NANOGEIOS Develops Revolutionary IRIS X Platform for Cost Effective Natural Hydrogen and Helium Detection

Published

16 hours ago

on

September 22, 2025

By

NANOGEIOS and AIDEN DIGITAL LABS have developed the IRIS-X platform, a breakthrough technology that reduces the cost of natural hydrogen exploration by 95-98% and cuts deployment time from 18 months to 8 weeks, enabling rapid and sustainable resource discovery.

A breakthrough in sustainable resource exploration technology

MIAMI, FL — September 18, 2025 — Growing global demand for clean energy and accelerating climate change mitigation efforts have intensified the search for sustainable alternatives. Natural hydrogen emerges as a promising zero-carbon energy solution due to its high energy density and clean combustion characteristics. Among exploration methods, conventional drilling and seismic surveying remain costly and inefficient; however, their dependence on extensive surface disturbance and multi-million dollar budgets limits large-scale implementation. Advanced subsurface detection offers a practical alternative by leveraging Earth’s natural hydrogen and helium resources, but high operational costs, extended timelines, and environmental impacts pose significant challenges for sustainable resource development.

To address this, a research team led by  Abdelmoumen Shad Serroune at NANOGEIOS Laboratory, in partnership with AIDEN DIGITAL LABS, developed a robust and cost-effective exploration platform capable of high-performance resource detection in complex geological environments. Dr. Serroune shares the motivation behind this breakthrough: “Conventional exploration methodologies, though established within the industry, face significant challenges including prohibitive costs, extended deployment periods, and environmental concerns that hinder commercialization. Our research is driven by the mission to develop economically viable and environmentally sustainable resource exploration technology to overcome these critical barriers.” Their findings were first published in the International Journal of Medical Science and Clinical Invention in July 2025. 

The team designed the IRIS-X (Integrated Reconnaissance and Imaging System – eXtended) an exploration platform that overcomes limitations of conventional drilling and seismic methods in natural hydrogen and helium exploration with the unique ability to be adapted for rare earth minerals, noble gases and minerals. They employed proprietary nano biomarker technology combined with advanced metal-oxide semiconductor (MOS) sensor arrays to synthesize selective detection matrices with crystalline-amorphous heterostructures. The nano-biomarkers are engineered to latch onto target molecules like hydrogen and helium with remarkable precision, achieving near-perfect binding efficiencies of 99.1% and 98.4%, respectively. During deployment, controlled nitrogen carrier injection facilitates uniform subsurface distribution while real-time magnetic tracking systems provide three-dimensional pathway reconstruction capabilities. 

Comprehensive field testing in Indonesia’s Padang region demonstrated outstanding resource detection performance. Over a 14-week validation campaign, IRIS-X exhibited exceptional analytical capabilities with 92% detection efficacy across variable lithological settings. 

The platform successfully quantified hydrogen accumulations totaling 18.5±2.3 million cubic meters while maintaining measurement precision within ±5% variance across challenging tropical conditions. Durability was confirmed through sustained operation across diverse geological formations including serpentinization zones and radiolysis environments. Crucially, the platform demonstrated exceptional cost-effectiveness with operational expenditures of $1,500,000 per campaign compared to conventional methods requiring $5-20 million, representing a 95-98% cost reduction while compressing deployment timelines from 6-18 months to 6-8 weeks.

The study highlights several distinct advantages. The IRIS-X platform synergistically combines high-sensitivity detection with optimized operational efficiency through radial well configurations covering 20,000 square meters per deployment with the ability to reach 100.000 sqm. The integrated AI-driven data processing prevents measurement artifacts while enabling real-time resource quantification. The overall design provides exceptional environmental stewardship with zero operational incidents and minimal surface disturbance. Together, these features enable cost-effective, scalable resource exploration directly from natural formations while reducing environmental impact and supporting decarbonization across energy-intensive sectors. 

AMS Serroune emphasizes, “Our breakthrough enables direct natural hydrogen and helium exploration from subsurface formations using advanced nano biomarker technology, opening vast geological resources for clean energy generation.” He adds, “The enhanced exploration systems demonstrate remarkable economic viability with 95-98% cost reduction compared to conventional methods, making resource discovery significantly more accessible for commercial development.“. 

Looking toward future applications, the IRIS-X architecture supports expansion into critical mineral exploration through aptamer-functionalized nano biomarker systems specifically engineered for uranium, thorium, lithium, cobalt, and rare earth element detection, positioning the technology at the forefront of the global energy transition. 

In conclusion, this work establishes a nano biomarker-mediated detection strategy that simultaneously addresses sensitivity, efficiency, and environmental challenges in subsurface resource exploration. Dr. Serroune notes, “Our technology will accelerate clean energy adoption by enabling rapid identification of natural hydrogen resources while maintaining superior environmental standards.” By enabling efficient and sustainable subsurface exploration, this study provides a blueprint for next-generation resource discovery, paving the way for large-scale clean energy infrastructure development. 

About AIDEN DIGITAL LABS
AIDEN DIGITAL LABS is a global research and development firm specializing in the integration of information technology, nanotechnology, and sustainable solutions, focused on AI-powered tools and environmental innovations for energy and resource management. 

About NANOGEIOS
NANOGEIOS is a global technology company headquartered in Miami, Florida, with research facilities in Osaka, Japan, and Paris, France. The company specializes in integrating nanotechnology, artificial intelligence, and advanced sensing to revolutionize resource identification and exploration through the IRIS-X platform. 

Contact:
Media Relations: Helena Dilbar S. 
Investor Relations: Professor Kazushi & AMS Serroune
Website: www.iris-exploration.com 

Email: contact@aiden.ventures 

Email: contact@nanogeios.io 

Publication: IJCNIS

Publication: SSRN Elsevier

Publication: Valley International 

Media Contact

Organization: GEIOS TECHNOLOGIES

Contact Person: Sandra Lebiewicz

Website: https://www.geios.net

Email: Send Email

Contact Number: +12396036828

Address:3401 N. MIAMI, AVE. STE 230

Address 2: Building B34-2nd Floor

City: MIAMI

State: FLORIDA

Country:United States

Release id:34272

The post NANOGEIOS Develops Revolutionary IRIS X Platform for Cost Effective Natural Hydrogen and Helium Detection appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us